Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study

Laura Amado-Rodríguez1,2,3,4†, Estefania Salgado del Riego5†, Juan Gomez de Ona3,6,7, Inés López Alonso2,3,4, Helena Gil-Pena3,8, Cecilia López-Martínez2,3,4, Paula Martín-Vicente2,3,4, Antonio Lopez-Vazquez3,6,7, Adrian Gonzalez Lopez2,9, Elias Cuesta-Llavona4,10, Raquel Rodriguez-García1,2,3, Jose Antonio Boga3,11, Marta Elena alvarez-Arguelles3,11, Juan Mayordomo-Colunga2,3,8,10, Jose Ramon Vidal-Castineira3, Irene Crespo2,3,12, Margarita Fernandez4, Loreto Criado12, Victoria Salvaders12, Francisco Jose Jimeno-Demuth13, Lluis Blanch2,14, Belen Prieto12,15, Alejandra Fernandez-Fernandez15, Carlos Lopez-Larrea3,6,8,12, Eliecer Coto3,6,10,12, Guillermo M Albaiceta1,2,3,4,12*

1Unidad de Cuidados Intensivos Cardiológicos. Hospital Universitario Central de Asturias, Oviedo, Spain; 2Centro de Investigación Biomédica en Red (CIBER)-Enfermedades Respiratorias. Instituto de Salud Carlos III, Madrid, Spain; 3Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain; 4Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain; 5Unidad de Cuidados Intensivos Polivalente. Hospital Universitario Central de Asturias, Oviedo, Spain; 6Red de Investigación Renal (REDINREN), Madrid, Spain; 7Servicio de Inmunología. Hospital Universitario Central de Asturias, Oviedo, Spain; 8Area de Gestión Clínica de Pediatría. Hospital Universitario Central de Asturias, Oviedo, Spain; 9Department of Anesthesiology and Operative Intensive Care Medicine CCM/CVK, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; 10Servicio de Genética Molecular. Hospital Universitario Central de Asturias, Oviedo, Spain; 11Servicio de Microbiología. Hospital Universitario Central de Asturias, Oviedo, Spain; 12Universidad de Oviedo, Oviedo, Spain; 13Servicio de Informática. Hospital Universitario Central de Asturias, Oviedo, Spain; 14Critical Care Center, Hospital Universitari Parc Taulí, Institut D’Investigació I Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain; 15Servicio de Bioquímica Clínica. Hospital Universitario Central de Asturias, Oviedo, Spain

*For correspondence: gma@crit-lab.org
*These authors contributed equally to this manuscript.
Competing interest: The authors declare that no competing interests exist.
Funding: See page 18
Preprinted: 07 July 2021
Received: 12 August 2021
Accepted: 06 December 2021
Published: 21 January 2022
Reviewing Editor: Evangelos J Giamarellos-Bourboulis, National and Kapodistrian University of Athens, Medical School, Greece

© Copyright Amado-Rodriguez et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Abstract

Background: Variants in IFIH1, a gene coding the cytoplasmatic RNA sensor MDAS, regulate the response to viral infections. We hypothesized that IFIH1 rs199076 variants would modulate host response and outcome after severe COVID-19.

Methods: Patients admitted to an intensive care unit (ICU) with confirmed COVID-19 were prospectively studied and rs199076 variants determined. Peripheral blood gene expression, cell populations, and immune mediators were measured. Peripheral blood mononuclear cells from healthy
volunteers were exposed to an MDA5 agonist and dexamethasone ex-vivo, and changes in gene expression assessed. ICU discharge and hospital death were modeled using rs1990760 variants and dexamethasone as factors in this cohort and in-silico clinical trials.

**Results:** About 227 patients were studied. Patients with the IFIH1 rs1990760 TT variant showed a lower expression of inflammation-related pathways, an anti-inflammatory cell profile, and lower concentrations of pro-inflammatory mediators. Cells with TT variant exposed to an MDA5 agonist showed an increase in IL6 expression after dexamethasone treatment. All patients with the TT variant not treated with steroids survived their ICU stay (hazard ratio [HR]: 2.49, 95% confidence interval [CI]: 1.29–4.79). Patients with a TT variant treated with dexamethasone showed an increased hospital mortality (HR: 2.19, 95% CI: 1.01–4.87) and serum IL-6. In-silico clinical trials supported these findings.

**Conclusions:** COVID-19 patients with the IFIH1 rs1990760 TT variant show an attenuated inflammatory response and better outcomes. Dexamethasone may reverse this anti-inflammatory phenotype.

**Funding:** Centro de Investigación Biomédica en Red (CB17/06/00021), Instituto de Salud Carlos III (PI19/00184 and PI20/01360), and Fundació La Marató de TV3 (413/C/2021).

**Editor's evaluation**
Authors present an interesting approach of COVID-19 multiorgan failure and loss of homeostasis attributed to modified adaptive immune response due to presence/absence of MDA5 polymorphism(rs1990760). Data presented by authors are very interesting representing novel scientific work that adds new and potentially pivotal information to existing knowledge. Key data presented strongly support an individualized approach during COVID-19 pandemic that could eventually alter therapeutic algorithm regarding dexamethasone administration implemented for these patients.

**Introduction**
The spectrum of disease after infection by SARS-CoV-2 (COVID-19) may range from mild respiratory symptoms to a severe form of lung injury fulfilling acute respiratory distress syndrome (ARDS) criteria (Grasselli et al., 2020). In these severe cases, systemic response to infection may be associated with multiorgan failure and death (Du et al., 2020). Therefore, outcomes in critically ill COVID-19 patients are related not only to viral clearance, but also to preservation of homeostasis.

The mechanisms responsible for the development of severe forms of COVID-19 have not been fully elucidated, but non-adaptative inflammatory responses play a central role. The only strategies that have decreased mortality in this population, steroids (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020) and blockade of the IL-6 pathway (REMAP-CAP Investigators et al., 2021), aim to limit this exacerbated immune response to prevent organ dysfunction.

The human gene IFIH1, located in the reverse strand of chromosome 2, encodes MDA5, a helicase that acts as a cytoplasmatic virus receptor. After binding to a viral RNA strand, MDA5 interacts with a mitochondrial adapter (MAVS, mitochondrial antiviral signaling protein), triggering the transcription of type-1 interferon genes and ultimately the systemic inflammatory response. In humans, the rs1990760 polymorphism encodes a variant of the IFIH1 gene (NM_022168: c.2836G > A [p.Ala946Thr]) that has been related to different susceptibility to viral infections and autoimmune disorders (Gorman et al., 2017). By regulation of IFN-dependent pathways, IFIH1 participates in a feedback loop that ultimately modulates viral clearance and host inflammatory responses. In experimental models of Coxsackie virus infection, TT variants in rs1990760 result in lower pro-inflammatory cytokine levels without a major reduction in viral clearance (Domsgen et al., 2016).

Although the role of this variant in Coronavirus infections has not been explored, it has been proposed that the rs1990760 TT variant could confer resistance to SARS-CoV-2 infection and that differences in allelic frequencies could explain the epidemiological features of the pandemic in different countries (Maiti, 2020). We hypothesized that, once infection is established, the inflammatory response in severe COVID-19 patients could be conditioned by IFIH1 variants. To test this hypothesis, we prospectively followed a cohort of critically ill patients with confirmed infection by...
**Materials and methods**

**Study design**

This single-center prospective, observational study was approved (ref. 2020/188) by the Clinical Research Ethics Committee of Principado de Asturias (Spain). Informed consent was obtained from each participant or next of kin. Given the exploratory nature of the study objective and the absence of previous data, no formal sample size calculations were performed. The study started after approval from the ethics committee and finished in December 2020, after the second pandemic wave.

All patients with confirmed SARS-CoV-2 infection (Escudero et al., 2020) and meeting the Kigali modification (Riviello et al., 2016) of ARDS criteria (to include patients without mechanical ventilation) from March 16, 2020 to December 10, 2020 were included in the study. Exclusion criteria were age <18, any condition that could explain the respiratory failure other than COVID-19, do not resuscitate orders or terminal status, or refusal to participate. Patients were followed until hospital discharge, and clinical and analytical data collected. The main outcome was intensive care unit (ICU) discharge alive and spontaneously breathing. Secondary outcome was hospital discharge.

All biochemical analyses (cytokine measurements, RNAseq, estimation of cell populations…, see below) were performed by researchers blinded to genotype and outcome.

**SARS-CoV-2 detection and quantification**

The presence of SARS-CoV-2 was analyzed by detecting viral genome using a multiple quantitative retrotranscriptase (RT)-PCR. Nucleic acids were purified by MagNa Pure 96 System (Roche, Geneva, Switzerland) from the swabs transport medium. The extracts were subjected to an amplification reaction using TaqMan Fast 1-Step Master Mix (Life Technologies, Carlsbad, CA) supplemented with a mixture of primers (Thermo Fisher Scientific, Walthan, MA) and TaqMan MGB probes (Applied Biosystems, Foster City, CA) directed against ORF1ab and N genes (Supplementary file 1a). Amplifications

SARS-CoV-2, in which peripheral blood gene expression, cell populations, concentrations of immune mediators, and clinical outcomes were studied and related to rs1990760 variants.
and subsequent analysis were carried out using the Applied Biosystems 7500 Real-Time PCR System (Escudero et al., 2020). Amplification of viral genes with a Ct number lower than 35 was considered positive. Viral load was normalized by the number of cells and expressed as copies/1000 cells, as previously described (Gómez-Novó et al., 2018). Clearance of SARS-CoV-2 was evaluated by fitting viral load in tracheobronchial samples after its peak value over time using an exponential decay function and calculation of viral clearance half-life (λ, Viral Clearance).

Genotyping
DNA was extracted from total blood leukocytes (1 ml) with an automated equipment (Promega Maxwell). IFI11 rs1990760 C/T polymorphism determined by real-time PCR with TaqMan genotyping master mix (Life Technologies) and TaqMan probes (Thermo Fisher Scientific, assay C_2780299_30) in an ABI-7500 device. The genotyping strategy was validated by Sanger sequencing of selected individuals from the three genotypes. Based on previous data showing that patients with a TT genotype have a different immune response compared to CC and CT (Wawrusiewicz-Kurylonek et al., 2020; Zhang et al., 2018), patients with these two variants were grouped and compared against the TT group.

Blood sampling
Two blood samples were taken in the first 24 hr after ICU admission. No patient had received steroids at the time of sampling. About 3 ml of blood was collected in Tempus tubes (Thermo Fisher Scientific) for RNA isolation and immediately stored at –80°C. Additional 5 ml was collected in a Vacutainer serum tube (BD Biosciences), and isolated by centrifugation, and stored at –80°C until analysis.

RNAseq
After thawing, blood from Tempus tubes was diluted in phosphate-buffered saline (PBS) (1:3 v/v) and centrifuged at 3000 rpm for 30 min. Supernatant was discarded and the pellet resuspended in TRIzol (Sigma-Aldrich, Poole, UK) and precipitated overnight with isopropanol at –20°C. After centrifugation, RNA pellets were washed with 70% ethanol and resuspended in RNAse-free water. RNA quality was assessed using a TapeStation, and only samples with a RIN (RNA integrity number) above 8 were analyzed.

RNA sequencing was performed using Ion AmpliSeq Transcriptome Human Gene Expression Kit, in an Ion S5 GeneStudio sequencer (Ion Torrent). Briefly, 10 ng of total RNA was retrotranscribed and the obtained cDNA used for library synthesis using Ion AmpliSeq Transcriptome kits to amplify all the canonical human transcripts. After template preparation in an automated Ion Chef Instrument, semiconductor 540 chips were run in an Ion S5 GeneStudio sequencer. Torrent Suite software was used for base calling, alignment, and sequence quality controls. The generated FASTQ files (available at Gene Expression Omnibus, accession numbers GSE168400 and GSE 177025) were mapped against a reference transcriptome (obtained from http://refgenomes.databio.org) and transcripts counted using Salmon v1.4 software (Patro et al., 2017). Raw counts were compared between genotypes using the DESeq2 library (Love et al., 2014). The log₂-fold change between variants for each gene and the adjusted p-value (corrected using a false discovery rate of 0.05) were calculated and analyzed using Ingenuity Pathway Analysis (Qiagen, USA) to identify overrepresented gene sets and networks. Over the identified network, in-silico effects of IFI11 downregulation and addition of exogenous dexamethasone were performed.

Peripheral blood cell populations
Circulating cell populations were estimated from gene expression using a previously validated deconvolution algorithm (Vallania et al., 2018). Using a reference expression matrix, proportions of 20 different cell lines were calculated. Only cell lines present in more than five samples were considered. As a quality check, we analyzed the correlation between estimated and measured lymphocyte percentages. The obtained correlation coefficient was 0.61 (Figure 3—figure supplement 1). It must be noted, however, that the deconvolution method estimates proportions over transcriptionally active cells, which may not be equivalent to the obtained cell count (as there may be inactive cells in the latter).

Inflammatory mediators
A panel of inflammatory mediators was studied in serum from patients not receiving steroids during their first ICU day. Serum concentrations of interferons (IFN)-β, -γ and -λ, tumor necrosis factor...
(TNF-α, interleukins (IL)-1β and -6, and chemokines CXCL8, CXCL9, CXCL10, CXCL16, CCL2, CCL3, CCL4, and CCL7 were measured using a multiplexed assay (Luminex custom panel). Concentrations below the lower limit of detection for a given mediator were replaced with half of that limit.

**Ex-vivo experiments**

To study the potential interferences between *IFIH1* rs1990760 variants and dexamethasone predicted by in-silico analyses, an ex-vivo experiment was designed. Blood samples from healthy volunteers (genotyped for *IFIH1* rs1990760 variants using DNA obtained from buccal swabs) were collected in EDTA tubes and immediately processed. Peripheral blood mononuclear cells (PBMCs) were isolated via density-gradient centrifugation with Lymphoprep (Axis-Shield PoC AS, Oslo, Norway). Cells were washed with red blood cell lysis buffer (NH₄Cl 0.1 M, KHCO₃ 0.01 M, EDTA 0.1 mM in dH₂O, pH 7.33) and PBS before being resuspended in RPMI-1640 (Gibco, USA) + 10% fetal bovine serum (FBS). Cells were seeded in 12-well plates at a final concentration of 1.5×10⁶ PBMC/ml and cultured at 37°C and 5% CO₂ in presence of medium/FBS, medium/FBS plus a MDA5 ligand (1 µg/ml high-molecular weight poly-i:C/LyoVec, Invivogen, USA), or medium plus the MDA5 ligand and 10 µM dexamethasone (Kern Pharma, Spain). Although poly-i:C may bind to both RIG-I and MDA-5, long (high-molecular weight) poly-i:C binds specifically to MDA-5 (Kato et al., 2008). After 24 hr, cells were collected and homogenized in TRIzol for RNA extraction. 500 ng of total RNA was retrotranscribed into cDNA using an RT-PCR Kit (High-capacity cDNA rt Kit, Applied Biosystems, USA). Expression of *STAT1*, *STAT3*, *FOXO3*, *IL6*, and *GAPDH* was quantified using 5 ng of cDNA per well and in triplicate for each sample. SYBR Green Power up (Thermo Fisher Scientific) and 10 µM of the corresponding primers (Supplementary file 1b) were used in all the experiments. The relative expression of each gene was calculated as 2⁻ⁿᶜᵗ(gene of interest) – nᶜᵗ(GAPDH).

**Clinical trial simulations**

Data from the RECOVERY trial were extracted and used to estimate risk ratios (RRs) for each rs1990760 variant, with and without steroids (see online Appendix for details). With these data, a survival model was developed and used to simulate scenarios with different allelic frequencies and baseline risks of death. Hazard ratios (HRs) for 28-day mortality were calculated from these simulations.

**Statistical analysis**

Data are shown as median (interquartile range). All data points and sample sizes represent individual patients/biological replicates. Comparisons between *IFIH1* variants were done using Wilcoxon or ANOVA tests, and p-values corrected using a false discovery rate of 0.05. Results from the ex-vivo model were fitted to a mixed-effects model including experimental group and genotype as covariates, and post hoc comparisons evaluated using Holm’s correction. No outliers were discarded.

Survival was analyzed using competing risks, Cox regression model, with ICU/hospital discharge alive and spontaneously breathing and death as competing risks, using the Aalen-Johansen estimator, as previously described (Barbaro et al., 2020). This competing-risks framework is needed as patients discharged alive have a low probability of death, so censoring at the time of discharge using a standard Kaplan-Meier approach would lead to biased observation, as the probability of death is different than in those still followed (i.e., informative censoring). Patients with an rs1990760 CC/CT variant not treated with steroids were considered the reference category in all the analyses.

All the analyses and plots were performed using the R 4.0.1 statistical environment (R Development Core Team, 2020) with the packages data.table (Dowle and Srinivasan, 2021), multcomp (Hothorn et al., 2008), survival (Therneau, 2020), MetaIntegrator (Haynes et al., 2017), and ggplot2 (Wickham, 2016, p. 2).

**Results**

**Study cohort**

About 250 patients were admitted in ICU due to suspected or confirmed COVID-19. Among these, 227 were included in the study. The study flow chart and reasons for exclusion are shown in Figure 1. Basic demographic and clinical data are shown in Table 1. *IFIH1* rs1990760 variants in this population met Hardy-Weinberg conditions (53 CC, 110 CT, 64 TT, chi-square p=0.19). There were no differences
Figure 1. Patient study flow chart. From 250 patients admitted to the participant ICUs during the study period, 227 were included in the study and classified according to the IFIH1 rs1990760 variants and prescription of steroid therapy. Peripheral blood samples for gene expression (N=41) and quantification of immune mediators (N=28) were taken in the first day after ICU admission in patients not receiving steroids. All patients were followed up until death or hospital discharge.
Table 1. Clinical characteristics of the study cohort.
COPD: Chronic Obstructive Pulmonary Disease. Values are shown as absolute count or median (interquartile range). PBW: Predicted body weight. NIV: Non-invasive ventilation. PEEP: Positive End-Expiratory Pressure. *p-values calculated for proportion over the number of intubated patients.

|                  | Overall (n=227) | TT (n=65) | CC/CT (n=162) | P-value |
|------------------|----------------|-----------|---------------|---------|
| **Demographics** |                |           |               |         |
| Age (years)      | 67 (60–75)     | 68.5 (63–75.25) | 66 (58–75) | 0.123   |
| Sex              |                |           |               |         |
| Male             | 174 (77)       | 47 (72)   | 127 (78)      | 0.327   |
| Female           | 53 (23)        | 18 (28)   | 35 (22)       |         |
| **Race**         |                |           |               |         |
| Black            | 3 (1.5)        | 1 (2)     | 2 (1.5)       |         |
| White            | 207 (91)       | 62 (95)   | 146 (90)      |         |
| Latino           | 15 (7)         | 2 (3)     | 13 (8)        | 0.527   |
| Asian            | 1 (0.5)        | 0         | 1 (0.5)       |         |
| **Body mass index (kg/m²)** | 30 (27–33) | 30 (26–33) | 30 (27–32) | 0.592   |
| **Days since symptom onset** | 8 (6–11) | 8 (6–10) | 8 (6–11) | 0.873   |
| **Days from hospital admission to ICU admission** | 2 (1–4) | 2 (1–3) | 2 (1–4) | 0.841 |
| **APACHE-II score** | 15 (12–18) | 15.5 (13–18) | 14 (11—18) | 0.177   |
| **Comorbidities** |                |           |               |         |
| Arterial hypertension | 132 (58) | 38 (59) | 94 (58) | 0.932   |
| Diabetes         | 51 (23)        | 14 (22)   | 37 (23)       | 1       |
| Chronic kidney disease | 15 (7) | 5 (8) | 10 (6) | 0.743   |
| COPD             | 17 (8)         | 7 (11)    | 10 (6)        | 0.339   |
| Cirrhosis        | 2 (1)          | 1 (2)     | 1 (0.5)       | 1       |
| **Neoplasms**    |                |           |               |         |
| No               | 215 (95)       | 62 (95)   | 154 (95)      |         |
| Active           | 10 (4)         | 3 (5)     | 7 (3.5)       |         |
| Past             | 2 (1)          | 0         | 2 (1.5)       | 0.669   |
| **Immunosuppresive drugs (incl. steroids)** | 5 (2) | 3 (5) | 2 (1.5) | 0.142   |
| **Lung function at ICU admission** |                |           |               |         |
| **Ventilation at admission** |                |           |               |         |
| Spontaneous /NIV | 38 (17)        | 11 (17)   | 27 (17)       |         |
| Controlled invasive ventilation | 187 (82.5) | 53 (82) | 135 (83) |         |
| Pressure support ventilation | 1 (0.5) | 1 (2) | 0 | 0.278 |
| FiO₂              | 0.5 (0.4–0.6)  | 0.5 (0.4–0.7) | 0.5 (0.4–0.6) | 0.104 |
| PaO₂/FiO₂ (mmHg)  | 204 (155–267)  | 185 (142–226) | 218 (162–282) | 0.007 |
| PaCO₂ (mmHg)      | 43 (39–47)     | 44 (39–47) | 43 (39–48)   | 0.924   |
| Respiratory rate (min⁻¹) | 18 (16–20) | 18 (16–20) | 18 (16–22) | 0.929   |

Table 1 continued on next page
in comorbidities or clinical data at admission between genotypes other than a lower \( \text{PaO}_2/\text{FiO}_2 \) ratio in patients with a TT variant (Table 1).

**IFIH1 rs1190760 variants and inflammatory response to SARS-CoV-2**

Gene expression in peripheral blood during the first day of ICU admission was profiled in 42 patients who did not receive steroid therapy at that time (11, 19, and 12 with rs1990760 TT, CT, and CC genotypes, respectively). Expression of *IFIH1* was significantly lower in patients with the TT genotype (Figure 2A and Figure 2—figure supplement 1). Comparison of peripheral blood gene expression between patients with TT and CT/CC variants yielded significant differences in 179 genes (Figure 2B–C, Supplementary file 2). Visual inspection of the heatmap reveals that differences are quantitative rather than qualitative. Ingenuity pathway analysis revealed several gene networks involved in the regulation of the inflammatory response among the differentially expressed genes (Figure 2D and Figure 2—figure supplement 2). In-silico predictions suggest that *IFIH1* downregulation (such as in patients with the rs1990760 TT variant) decreases the expression of pro-inflammatory pathways (Figure 2—figure supplement 3).

Then we assessed the immunological consequences of these differences in gene expression and cell populations. There were no statistically significant differences in inferred percentages of classic CD14+ monocytes, circulating plasma cells, M2 macrophages, and CD56dim NK cells, between genotypes. Patients with the TT genotype showed an increase in hematopoietic precursors and myeloid dendritic cells (Figure 3).

Serum cytokines were measured at ICU admission in 28 patients (8, 10, and 10 with TT, CT, and CC genotypes, respectively). There were no differences in any of the measured interferons, which were below the limit of detection in a large proportion of patients. Patients with the TT genotype showed lower levels of pro-inflammatory mediators, including IL-6, CXCL10, CXCL16, and CCL7 (Figure 4).
There were no significant differences in any of the measured cytokines between patients with CC and CT variants (Figure 4—figure supplement 1).

**Ex-vivo effects of dexamethasone in IFIH1 variants**

During the study period, dexamethasone was added to COVID-19 treatment based on results from published trials (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020). An in-silico analysis focused on the interactions between IFIH1 and steroids suggested that dexamethasone could disrupt some of the effects caused by IFIH1 downregulation.
Specifically, dexamethasone may change expression of several IFIH1-dependent genes, including STAT1, STAT3, or FOXO3 among others. To test these predictions, an ex-vivo experiment using PBMCs from healthy volunteers with different IFIH1 rs1990760 variants (n=5, 6, and 7 for CC, CT, and TT variants, respectively) was performed. Cells were collected and exposed to poly I:C, to mimic SARS-Cov-2 infection, and dexamethasone. Compared to exposure to poly I:C alone, dexamethasone had no effect on STAT1 (Figure 5A) or STAT3 (Figure 5B) expression. However, the steroid increased the expression of FOXO3 (Figure 5C) and IL6 (Figure 5D) only in cells with the TT variant. These results suggest that dexamethasone may alter the inflammatory response triggered by MDA5 activation in those patients with the TT variant of the gene.

**Figure 3.** Differences in circulating cell populations according to IFIH1 rs1990760 variants (31 and 11 samples from patients with a CC/CT or TT variant, respectively). Proportions of each cell line were estimated by deconvolution of RNAseq data. P-values were calculated using a Wilcoxon test and adjusted using the Benjamini-Hochberg method for a false discovery rate of 5%. Points represent individual patient data. In boxplots, bold line represents the median, lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles) and upper and lower whiskers extend from the hinge to the largest or smallest value no further than 1.5 times the interquartile range.

The online version of this article includes the following source data and figure supplement(s) for figure 3:

**Source data 1.** Raw data used in Figure 3, showing different peripheral cell populations obtained after deconvolution of RNAseq data.

**Figure supplement 1.** Correlation between measured and estimated (from deconvolution analysis) lymphocyte percentages in peripheral blood.
Figure 4. Differences in serum immune mediators according to IFIH1 rs1990760 variants (19 and 8 samples from patients with a CC/CT or TT variant, respectively). P-values were calculated using a Wilcoxon test and adjusted using the Benjamini-Hochberg method for a false discovery rate of 5%. Points represent individual patient data. In boxplots, bold line represents the median, lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles) and upper and lower whiskers extend from the hinge to the largest or smallest value no further than 1.5 times the interquartile range.

The online version of this article includes the following source data and figure supplement(s) for figure 4:

Source data 1. Raw data used in Figure 4, showing serum concentration of inflammatory mediators.

Figure supplement 1. Serum inflammatory mediators in patients with a CC or CT variant in rs1990760 polymorphisms.
Figure 5. Expression of transcription factors STAT1 (A, p=0.012, no significant differences between variants in post hoc tests), STAT3 (B, p=0.443) and FOXO3 (C, p=0.002), and cytokine IL6 (D, p<0.001) induced by MDA5 activation using high molecular weight poly-1:C (a viral RNA analog) and dexamethasone in peripheral mononuclear blood cells. Results were fitted using a mixed-effects linear model including cell donor as a fixed effect and experimental group and genotype as random effects. Pairwise p-values lower than 0.05 (using Holm’s correction) are shown. Points represent individual patient data. In boxplots, bold line represents the median, lower and upper hinges correspond to the first and third quartiles (the 25th and 75th percentiles), and whiskers extend to show all data points within 1.5 times the interquartile range from the hinges.

Figure 5 continued on next page
Impact of IFIH1 variants on outcomes in critically ill COVID-19 patients

Median follow-up was 25 days (interquartile range 16–39 days) and 27 days in survivors (interquartile range 17–44 days). There were no differences in ICU length of stay among groups (Supplementary file 1c). ICU survival and hospital mortality were modeled using IFIH rs1990760 genotype and steroid treatment as interacting covariables. There were no significat differences in the main clinical characteristics among the resulting groups (Supplementary file 1c). Regarding ICU survival (Figure 6A and Supplementary file 1c), 27 out of 35 patients with CC/CT alleles who did not receive steroids were discharged alive and spontaneously breathing from the ICU (HR: 1, used as reference). In patients with this variant, dexamethasone was not related to a better outcome (98 out of 128 patients discharged, HR: 1.20 [0.78–1.38], p=0.41). All patients with the TT allele (n=14) who did not receive steroids were discharged alive (HR: 2.49 [1.29–4.79], p=0.012). Steroid treatment in patients with the TT variant was related to the loss of this benefit (32 out of 50 patients discharged alive, HR: 1.03 [0.62–1.72], p=0.91).

Hospital mortality is shown in Figure 6B and Supplementary file 1c. There were nine hospital deaths in patients with the CT/CC genotypes not treated with steroids (out of a total of 35 patients), and 27 out of 128 hospital deaths when treated with steroids, resulting in HR of 1.11 [0.52–2.37] (p=0.80). All patients with the TT allele who were not treated with steroids survived after their hospital stay (HR 1.23×10⁻⁷, confidence intervals, and p-value cannot be computed due to the absence of events). Patients with the TT allele and treated with steroids showed a worse outcome (19 deaths in 50 patients, HR: 2.19 [1.01–4.87], p=0.05).

To investigate the causes responsible for the differences in mortality among groups, we first quantified viral load at diagnosis (Figure 6C) and clearance after its peak value (Figure 6D). There were no differences in these parameters related to IFIH1 variants or treatment groups. We also compared serum IL-6 levels at ICU admission and 1 week later. Compared to patients with CC/CT variants not treated with steroids, patients with the same genotype but receiving dexamethasone and patients with the TT variant not receiving steroids showed lower levels of IL-6 at admission (Figure 6E). After 1 week (Figure 6F), serum IL-6 levels remained lower in patients receiving dexamethasone with the CC/CT variant and in those with the TT variant and not treated with this drug. However, IL-6 levels were higher in those with the TT variant and treated with steroids, in line with our ex-vivo findings.

To explore the mechanisms behind these differences, peripheral blood gene expression at ICU day 4 was compared between patients treated with or without steroids for each rs1990760 variant. IFIH1 expression decreased in patients with rs1990760 CC/CT variants treated with steroids, but not in those with a TT variant (Figure 6G). In opposite, steroids increased FOXO3 expression only in patients with a TT variant (Figure 6H), resembling the results from the ex-vivo experiments. IL6 gene raw counts at day 4 were below 5 in all the patients, and thus not compared. When the whole transcriptomes were compared, steroids significantly changed the expression of 58 genes in patients with a CC/CT variant and 23 in patients with a TT variant (Supplementary file 3). Overall, changes in gene expression were qualitatively different between variants, with only three genes in common (Figure 6I and Figure 6—figure supplement 1).

In-silico clinical trials

These findings may support the hypothesis that COVID-19 populations with a low proportion of the rs1990760 TT variant would show a better response to dexamethasone. To explore this prediction, data from the RECOVERY trial (RECOVERY Collaborative Group et al., 2021) were examined. The T-allele frequency in populations from a Black/Asian ancestry is 0.13 (data available at https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx), so only 1.7% has a TT variant. In these populations, RR was 0.7 (0.51–0.95), whereas in patients from a White ancestry (with a T allele frequency of 0.61), RR increased to 0.9 (0.8–1.2).
Figure 6. Outcomes according to IFIH1 rs1990760 variants and treatment with dexamethasone. (A) Cumulative incidence of ICU discharge alive and spontaneously breathing for each group. (B) Cumulative incidence of hospital death for each group. Outcomes were modeled as competing events. (C) Viral load at diagnosis for each group (p=0.888). (D) Viral clearance evaluated as half-life of an exponential decay function calculated from the maximal viral load in each patient (p=0.056, no significant differences in post hoc tests). (E, F) Serum IL-6 concentrations during the first day (E, p<0.001) and
7 days (F, p=0.014) after ICU admission for each group. Differences among groups in panels (C–F) were evaluated using an analysis of the variance. Pairwise p-values lower than 0.05 (using Holm’s correction) are shown. (G, H) Changes in IFIH1 (G) and FOXO3 (H) expression in day 4 of ICU stay for each group (n=6 and 7 for CC/CT variants without and with dexamethasone, respectively, n = 4 and 4 for TT variant without and with dexamethasone, respectively). (I) Genes with dexamethasone-induced changes in gene expression in ICU day four in each rs1990760 variant. Points represent individual patient data. In boxplots, bold line represents the median, lower and upper hinges correspond to the first and third quartiles (25th and 75th percentiles) and upper and lower whiskers extend from the hinge to the largest or smallest value no further than 1.5 times the interquartile range.

The online version of this article includes the following figure supplement(s) for figure 6:

**Figure supplement 1.** Heatmaps with the differentially expressed genes in response to steroids in patients of each rs1990760 variant.

Using these data, RRs related to each rs1990760 variant, with and without steroids, were extracted and a survival model developed (see online supplement for details). A simulation including 500 patients from each rs1990760 variant and treatment arm (placebo or dexamethasone) showed a significant reduction in mortality with steroids in patients with a CC/CT variant, but not in those with a TT variant (Figure 7A). In patients not-receiving steroids, HRs related to a TT variant, compared to CC/CT variants, were independent of the allelic frequency (Figure 7B). Simulations of steroid therapy with different allelic frequencies showed that HRs in each specific variant remained constant whereas the effect of steroids in the overall population was dependent on the allele distribution (Figure 7C and Figure 7—figure supplement 1).

**Discussion**

Our results show that critically ill patients with the TT variant in the IFIH1 rs1990760 polymorphism have an attenuated inflammatory response to severe SARS-CoV-2 infection, leading to a decreased mortality. In this selected population, treatment with steroids has no immunomodulatory effects and could be related to worse outcomes. These results confirm the impact of the host response on patients’ outcomes and suggest that patient geno/phenotypes should be taken into account to prescribe steroids in this setting.

Host response is a major determinant of outcome in critically ill patients, including those with COVID-19. Several genetic variants involved in the inflammatory response have been related to SARS-CoV-2 infection and its severity (Bovijn et al., 2020; Gómez, 2021; Zhang et al., 2020). Activation of immune responses causes local and systemic inflammation, aimed to block viral replication. However, exacerbation of these responses can cause organ damage even after virus clearance. Our results recapitulate previous findings in COVID-19 describing the release of pro-inflammatory mediators, NK cell exhaustion, monocyte dysregulation, and emergency hematopoiesis (Schulte-Schrepping et al., 2020; Wen et al., 2020; Wilk et al., 2020). Some of our findings in patients with the rs1990760 TT variant, including lower levels of circulating pro-inflammatory molecules and a shift toward anti-inflammatory cell populations (hematopoietic precursors, M2 macrophages, or CD56dim NK cells) have been linked to better outcomes in other observational studies (Maucourant et al., 2020).

Recognition of viral RNA by cytosolic receptors leading to the ultimate induction of expression of types I and II IFNs as part of the activation of innate antiviral signaling cascades, may not only rely on MDA5 receptor but also on other retinoic acid-inducible gene (RIG)-I-like receptors, or on the endosomal Toll-like receptor 3 (TLR3) (Takeuchi and Akira, 2010). Interestingly, no differences were found in serum interferons levels. This may be explained by several factors. Most patients included in our study had serum IFNs levels below the inferior detection threshold. This result is similar to the one reported by Galani et al., 2021, where IFN-lambda and type I IFN production were both diminished and delayed in moderate-to-severe COVID-19 patients followed up during hospitalization. In our study, IFNs levels were only measured on day 1 of ICU admission, precluding any conclusions regarding time-dependent changes on these mediators’ levels during, for instance, subacute or long-term infection.

More importantly, transcriptomic analysis did not reveal significantly different expression levels for IFIH1 gene after correction for multiple comparisons, although single-gene comparison showed a downregulated expression in patients with TT genotype. Although expression levels may be similar, full activation of an antiviral response triggering specific signaling intermediates and transcription factors, may vary between genotypes due to differences in MDA5 molecular architecture and function. The
Figure 7. In-silico clinical trials. (A) Mortality curves modeled using data from the RECOVERY clinical trial, for each rs1990760 variant and treatment allocation, assuming a sample size of 500 patients per group. (B) Effect of rs1990760 TT variants (expressed as hazard ratio, HR) in simulated clinical trials including 6000 patients from populations with different minor allele frequencies, assigned to standard care. (C) Effect of dexamethasone therapy according to rs1990760 variants and different minor allele frequencies in simulated clinical trials including 6000 patients. Minor allele frequencies were estimated according to reported race in several subsets of patients from the RECOVERY trial: European population (0.61), overall population (0.53), mechanically ventilated patients (0.47), and African American/Asian population (0.13). An intermediate value of 0.30 was added for illustrative purposes. Points and error bars represent the estimated HR and the corresponding 95% confidence interval.

The online version of this article includes the following figure supplement(s) for figure 7:

Figure supplement 1. Simulated survival curves corresponding to in-silico clinical trials testing dexamethasone in 6000 COVID-19 patients from populations with different allelic frequencies.
effect of rs1990760 on MDA5 function is related to modifications on the molecular architecture (Berke and Modis, 2012; Wu et al., 2013) and has been reported by several previous studies (Looney et al., 2015; Nejentsev et al., 2009).

Collectively, our findings raise the hypothesis that the TT variant could be related to an attenuated pro-inflammatory response. In line with this observation, a TT variant has been associated with lower pro-inflammatory cytokine levels in patients with lupus (Robinson et al., 2011; Zhang et al., 2018, p. 1) and in experimental viral infections (Domsgen et al., 2016).

Development of tolerance to viral diseases can be considered a major evolutionary adaptive response (Schneider and Ayres, 2008), and inhibition of pro-inflammatory responses has been proposed to improve the outcome of severe COVID-19 patients. Notably, pangolins, an intermediate host of coronaviruses (Xiao et al., 2020), lack functional IfiH1. It has been suggested that this deficiency reduces the inflammatory response to coronavirus infections (Fischer et al., 2020). IL-6 blockade (REMAP-CAP Investigators et al., 2021) or steroids (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020) are the only treatments that have improved the outcome of critically ill COVID-19 patients. However, mortality rates are still around 27–32% (REMAP-CAP Investigators et al., 2021; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2020), so new therapeutic approaches are warranted.

According to our results, the impact of the treatment with steroids along a given population may depend on intrinsic individual characteristics, allowing a personalized approach based on a specific genomic biomarker. In our study sample, patients with the IfiH1 rs1990760 TT variant constitute a population with a better prognosis, in whom treatment with dexamethasone may be reconsidered as it was associated to higher mortality rates. Indeed, as shown by the in-silico trials, any population enriched for patients with CC/CT variants in rs1990760 will show higher mortality rates and a better response to steriods, due to the low proportion of TT variants. Dexamethasone in patients receiving mechanical ventilation at inclusion in the RECOVERY trial had an HR of 0.64, compared to an HR of 0.83 in the whole population. Of note, the proportion of Black/Asian patients (with a low frequency of a T allele) in the mechanically ventilated group was 29%, but only 18% in the whole study population. To date, no other genomic markers of personalized therapies in critically ill patients have been identified.

The absence of differences in viral clearance and the late increase in IL-6 in these patients suggest that this worse outcome is more related to the disruption of ongoing immunoregulatory mechanisms than to antiviral responses. Our ex-vivo experiments do not fully elucidate the molecular mechanisms behind the interaction between TT variants and steroids, as the effects of FOXO3 upregulation and IL6 expression may be variable (Joseph et al., 2016), but clearly illustrate that this specific combination may disrupt the ongoing self-regulation of inflammation. Moreover, steroid-induced changes in gene expression are qualitatively different in patients of each variant.

Our findings point toward the therapeutic potential of MDA5 modulation in COVID-19, either induced by steroids or targeted by other drugs. Amelioration of MDA5-dependent RNA sensing could avoid an exacerbated inflammatory response without impairing viral clearance. In this sense, it has been described that the interferon response triggered by MDA5 is unable to control viral replication (Rebenderne et al., 2021). However, genetic ablation of IfiH1 results in increased viral loads and decreased cytokine production (Yin et al., 2021), so this approach must be viewed with caution.

It is unclear if these findings can be translated to other viral diseases. Steroids may decrease mortality in an unselected ARDS population (Villar et al., 2020), but the role of underlying genotypes has not been addressed. An experimental model of Coxsackie virus infection revealed lower IfiH1 and CXCL10 expression in cells with the TT variant (Domsgen et al., 2016), with no relevant differences in viral clearance. However, total absence of MDA5 results in impaired clearance of West Nile virus (Errett et al., 2013).

Our work has several limitations. First, the results must be validated in an independent cohort. Our in-silico simulations reinforce the external validity of our findings, but a pharmacogenomic analysis of patients included in clinical trials is warranted for confirmation. Second, steroid treatment was not randomized, so we cannot discard other underlying factors responsible for the observed differences. Although there could be confounding by indication, there were no baseline differences among groups suggesting a higher severity in steroid-treated patients. Moreover, there are significant differences between genotypes irrespective of the treatment received. In addition, in-silico and ex-vivo
experiments are congruent with the observed clinical results, supporting the differential effects of steroid therapy in IFIH1 rs1990760 variants. Third, the favorable outcome of patients with a TT allele without steroids is based on a small sample size. As steroids are now the standard of care for severe COVID-19, this sample size cannot be increased outside a hypothetical clinical trial focused on personalized steroid therapy according to IFIH1 rs1990760 variants. However, similar reduced numbers have served to identify other variants in the immune response (Bastard, 2020), and the related finding of increased mortality in this genotype after steroid therapy compared to all other variants is supported by a larger sample. In addition, our sample is representative of European population with a limited racial diversity that may have influenced our results, as the in-silico analyses further suggest. Finally, other studies Pairo-Castineira et al., 2020; Ellinghaus et al., 2020 have focused on the genetic variants linked to an increased risk of severe COVID-19, compared to non-infected populations. However, no genetic markers have been associated to mortality in cohorts of infected patients. According to our data, rs1990760 is linked to the outcome, but no inferences on susceptibility to severe COVID-19 can be extracted.

In summary, we have identified a genetic variant of IFIH1 that results in an ameliorated inflammatory response after severe SARS-CoV-2 infection. Patients with the rs1990760 TT genotype show a good outcome. However, this adaptive response was not observed in patients with a TT variant and treated with steroids. These findings suggest that the systemic response to severe COVID-19 is regulated by genetic factors that modulate the response to the infection and the prescribed therapy and, ultimately, may impact the outcome.

| Genotype | Patients | Standard care | Dexamethasone |
|----------|----------|---------------|---------------|
| CC/CT    | 2954     | a/1978        | b/976         |
| TT       | 1735     | (849 a)/1161  | (401-b)/574   |
|          | 4689     | 849/3139      | 401/1550      |

Acknowledgements

The authors want to thank all the personnel at the participating ICUs and laboratories for their support during the development of the study. In addition, the authors thank Salvador Villalgordo, Silvia Viñas, Salvador Balboa, Rodrigo Albillos, Cecilia del Busto, Emilio García-Prieto, Jose Antonio Gonzalo, Diego Parra, Lisardo Iglesias, José Alonso, Sérída Domínguez, and Alfredo González their additional efforts for sample collection.

Additional information

Funding

| Funder | Grant reference number | Author |
|--------|------------------------|--------|
| Instituto de Salud Carlos III | PI19/00184 | Carlos Lopez-Larrea |
| Instituto de Salud Carlos III | PI20/01360 | Guillermo M Albaiceta |
| Centro de investigación biomédica en red (CIBER)-Enfermedades respiratorias | CB17/06/00021 | Guillermo M Albaiceta |
| Fundación la Marató de TV3 | grant 413/C/2021 | Laura Amado-Rodríguez |
| Instituto de Salud Carlos III | CM20/00083 | Raquel Rodríguez-Garcia |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Laura Amado-Rodríguez, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Validation, Visualization, Writing
– original draft, Writing – review and editing; Estefanía Salgado del Riego, Investigation, Resources, Writing – review and editing; Juan Gomez de Ona, Data curation, Investigation; Inés López Alonso, Conceptualization, Data curation, Formal analysis, Investigation, Supervision, Validation, Writing – review and editing; Helena Gil-Pena, Data curation, Investigation, Supervision, Validation; Cecilia López-Martínez, Data curation, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – review and editing; Paula Martín-Vicente, Data curation, Formal analysis, Investigation, Writing – review and editing; Antonio Lopez-Vazquez, Raquel Rodriguez-Garcia, Marta Elena alvarez-Arguelles, Juan Mayordomo-Colunga, Jose Ramon Vidal-Castineira, Margarita Fernandez, Loreto Criado, Victoria Salvadore, Belen Prieto, Alejandra Fernandez-Fernandez, Investigation, Writing – review and editing; Adrian Gonzalez Lopez, Data curation, Formal analysis, Investigation, Software, Validation, Visualization, Writing – review and editing; Elias Cuesta-Llavona, Data curation, Investigation, Writing – review and editing; Jose Antonio Boga, Investigation, Methodology, Writing – review and editing; Irene Crespo, Investigation, Validation, Writing – review and editing; Francisco Jose Jimeno-Demuth, Formal analysis, Investigation, Software, Writing – review and editing; Lluis Blanch, Methodology, Supervision, Validation, Writing – review and editing; Carlos Lopez-Larraea, Conceptualization, Funding acquisition, Investigation, Methodology, Supervision, Validation, Writing – review and editing; Eliecer Coto, Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Supervision, Validation, Writing – review and editing; Guillermo M Albaiceta, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing

Author ORCIDs
Laura Amado-Rodriguez http://orcid.org/0000-0002-8793-0213
Juan Mayordomo-Colunga http://orcid.org/0000-0003-0997-4410
Guillermo M Albaiceta http://orcid.org/0000-0002-9276-3253

Ethics
Human subjects: This single-center prospective, observational study was approved (ref. 2020/188) by the Clinical Research Ethics Committee of Principado de Asturias (Spain). Informed consent was obtained from each participant or next of kin.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.73012.sa1
Author response https://doi.org/10.7554/eLife.73012.sa2

Additional files
Supplementary files
• Supplementary file 1. Supplementary Tables. 1a. Primers and probes used to detect SARS-CoV-2. 1b: Primers used for qPCR of human genes. 1c: Clinical characteristics of patients according to IFIH1 rs1990760 genotypes and dexamethasone therapy. Values are shown as absolute count or median (interquartile range). PBW: Predicted body weight. NIV: Non-invasive ventilation. PEEP: Positive End-Expiratory Pressure. *p-values calculated for proportion over the number of intubated patients.
• Supplementary file 2. Results of differential expression analysis between rs1990760 variants.
• Supplementary file 3. Changes in gene expression after steroid treatment in rs1990760 variants.
• Transparent reporting form
• Reporting standard 1. STROBE check list for cohort studies.

Data availability
RNA-seq data has been deposited in Gene Expression Omnibus (accession numbers GSE168400 and GSE177025). Code for in-silico clinical trials is available at https://github.com/Crit-Lab/IFIH1_simulation (copy archived at swh:1:rev:343c92a4ce58b831df7b289bf40b539db5298d0a). Source data files for figures 3, 4 and 5 have been provided. Patient-derived data related to this article are not publicly available out of respect for the privacy of the patients involved. De-identified clinical data will be shared with researchers with any proposal after review and approval by the local Ethics Committee and a signed data access agreement. All requests should be sent to the corresponding author (gma@crit-lab.org).
The following dataset was generated:

| Author(s) | Year | Dataset title | Dataset URL | Database and Identifier |
|-----------|------|---------------|-------------|-------------------------|
| Albaceta GM, López-Alonso I, López-Martínez C, Amado-Rodríguez L | 2021 | Peripheral blood gene expression according to IFIH1 rs1990760 variants in critically-ill COVID-19 patients | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE168400 | NCBI Gene Expression Omnibus, GSE168400 |
| Albaceta GM, López-Alonso I, López-Martínez C, Amado-Rodríguez L | 2021 | Effects of steroids on peripheral blood gene expression in COVID-19 patients according to rs1990760 variants | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE177025 | NCBI Gene Expression Omnibus, GSE177025 |

References

Barbano RP, MacLaren G, Boonstra PS, Iwashyna TJ, Slutsky AS, Tonna JE, Hyslop R, Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D. Extracorporeal Life Support Organization. 2020. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 396:1071–1078. DOI: https://doi.org/10.1016/S0140-6736(20)32008-0, PMID: 32987008

Bastard P. 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eaab4585. DOI: https://doi.org/10.1126/science.abd4585

Berke IC, Modis Y. 2012. MDA5 cooperatively forms dimers and ATP-sensitive filaments upon binding double-stranded RNA. The EMBO Journal 31:1714–1726. DOI: https://doi.org/10.1038/emboj.2012.19, PMID: 22314235

Blevin J, Lindgren CM, Holmes MV. 2020. Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. The Lancet. Rheumatology 2:e658–e659. DOI: https://doi.org/10.1016/S2665-9913(20)30345-3, PMID: 33015641

Crit-Lab. 2022. IFIH1_simulation. swh:1:rev:343c92a4ce58b831df7b289bf40b539db5298d0a. Software Heritage. https://archive.softwareheritage.org/swh:1:dir:191b32f9b0a371a6c0610fe7688b6ae38d19544e;origin=https://github.com/Crit-Lab/IFIH1_simulation;visit=swh:1:snp:2946993d2d56beebd48df4b93b447114a19070;anchor=s1:rev:343c92a4ce58b831df7b289bf40b539db5298d0a

Domsøg E, Lind K, Kong L, Hühn MH, Rasool O, van Kuppeveld F, Korsgren O, Lahesmaa R, Flosdøm-Tullberg M. 2016. An IFIH1 gene polymorphism associated with risk for autoimmunity regulates canonical anti-viral defence pathways in Coxsackievirus infected human pancreatic islets. Scientific Reports 6:39378. DOI: https://doi.org/10.1038/srep39378, PMID: 28000727

Dowle M, Srinivasan A. 2021. data.table: Extension of ‘data.frame’. Data.Frame. https://cran.r-project.org

Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, Wang X, Hu C, Ping R, Hu P, Li T, Cao F, Chang C, Hu Q, Jin Y, Xu G. 2020. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan A Retrospective Observational Study. The New England Journal of Medicine 383:1522–1534. DOI: https://doi.org/10.1056/NEJMoa2020283, PMID: 32558485

Errett JS, Suthar MS, McMillan A, Diamond MS, Gale M. 2013. The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. Journal of Virology 87:1323–1379. DOI: https://doi.org/10.1128/JVI.01488-13, PMID: 23696395

Ellinghaus D, Degenhartd F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernández J, Prati D, Baselli G, Asselta R, Tschachler E, Eckhart L. 2020. Pangolins Lack IFIH1/MDA5, a Cytoplasmic RNA Sensor That Initiates Stranded RNA. The EMBO Journal 39:1732–1737. DOI: https://doi.org/10.1038/s41896-020-00349-5, PMID: 33225382

Ernest Shackleton’s spirit. Intensive Care Medicine Experimental 8:68. DOI: https://doi.org/10.1186/s40635-013-0034-9, PMID: 33015641

Escudero D, Boga JA, Fernández J, Forcelledo L, Balboa S, Albillos A, Astola I, García-Prieto E, Álvarez-Argüelles ME, Martín G, Jiménez J, Vázquez F. 2020. SARS-CoV-2 analysis on environmental surfaces collected in an intensive care unit: keeping Ernest Shackleton’s spirit. Intensive Care Medicine Experimental 8:68. DOI: https://doi.org/10.1186/s40635-020-00349-5, PMID: 33015641

Fanning JJ, Rycus PT, Hyer SJ, Anders MM, Agerstrand CL, Hryniewicz K, Diaz R, Lorusso R, Combes A, Brodie D. Extracorporeal Life Support Organization. 2020. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 396:1071–1078. DOI: https://doi.org/10.1016/S0140-6736(20)32008-0, PMID: 32987008

Fan E, Bartlett RH, Tonna JE, Slutsky AS. 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370:eaab4585. DOI: https://doi.org/10.1126/science.abd4585

Gómez-Argüelles ME, Rojo-Alba S, Fernández A, Menéndez MJ, de Oña M, Melón S. 2018. Human respiratory syncytial virus load normalized by cell quantification as predictor of acute respiratory
tract infection. Journal of Medical Virology 90:861–866. DOI: https://doi.org/10.1002/jmv.29315642

Gorman JA, Hundhausen C, Errett JS, Stone AE, Allenbach RJ, Ege Y, Arkatkar T, Clough C, Dai X, Khim S, Pestal K, Liggitt D, Ceresaleti K, Stetson DB, James RG, Oukka M, Conannon P, Gale M, Buckner JH, Rawlings DJ. 2017. The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. Nature Immunology 18:744–752. DOI: https://doi.org/10.1038/nim.2017.86

Grassel G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, et al. 2020. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 323:1574–1581. DOI: https://doi.org/10.1001/jama.2020.5394

Haynes WA, Vallania F, Liu C, Eongen E, Tomczak A, Andres-Terré M, Lofgren S, Tam A, Deissereoth CA, Li MD, Sweeney TE, Khati P. 2017. EMPOWERING MULTI-COHORT GENE EXPRESSION ANALYSIS TO INCREASE REPRODUCIBILITY. Pacific Symposium on Biocomputing. 144–153. DOI: https://doi.org/10.1142/9789813207813_0015, PMID: 27896970

Hothorn T, Bretz F, Westfall P. 2008. Simultaneous inference in general parametric models. Biometrical Journal 50:346–363. DOI: https://doi.org/10.1002/bimj.200810425, PMID: 18481363

Joseph J, Ametepe ES, Haribabu N, Agbayani G, Krishnan L, Blais A, Sad S. 2016. Inhibition of ROS and upregulation of inflammatory cytokines by FoxO3a promotes survival against Salmonella typhimurium. Nature Communications 7:12748. DOI: https://doi.org/10.1038/ncomms12748, PMID: 27599659

Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, Hiiragi A, Dermody TS, Fujita T, Akira S. 2008. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. The Journal of Experimental Medicine 205:1601–1610. DOI: https://doi.org/10.1084/jem.20080091, PMID: 18591409

Looney BM, Xia CQ, Conannon P, Ostrov DA, Clare-Salzler MJ. 2015. Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDAS function and expression. Current Diabetes Reports 15:96. DOI: https://doi.org/10.1007/s11892-015-0656-8, PMID: 26385483

Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology 15:550. DOI: https://doi.org/10.1186/s13059-014-0550-8, PMID: 25516281

Maiti AK. 2020. The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics 72:387–391. DOI: https://doi.org/10.1007/s00221-020-01174-6, PMID: 32737579

Maucourant C, Filipovic I, Ponzetta A, Aleman S, Cornillet M, Hertwig L, Strunz B, Lentini A, Reinius B, Xia CQ, Concannon P, Ostrov DA, Clare-Salzler MJ. 2015. Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression. Current Diabetes Reports 15:96. DOI: https://doi.org/10.1007/s11892-015-0656-8, PMID: 26385483

Mazurek C, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, Furniss J, Richmond A, Gountouna E, Wrobel N, Harrison D, Wang B, Wu Y, Meynert A, Griffiths F, Oosthuyzen W, et al. 2020. Genetic mechanisms of critical illness in Covid-19. Nature 591:92–98. DOI: https://doi.org/10.1038/s41586-020-03065-y

Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. 2017. Salmon provides fast and bias-aware quantification of transcript expression. Nature Methods 14:417–419. DOI: https://doi.org/10.1038/nmeth.4197, PMID: 28263959

R Development Core Team. 2020. R: A language and environment for statistical computing. Vienna, Austria. R Foundation for Statistical Computing. http://www.R-project.org

Rebendenn S, Arnaud-Arnould M, Moncorgé O, Goujon C. 2021. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. Journal of Virology 20:JVI.02415-20. DOI: https://doi.org/10.1128/JVI.02415-20, PMID: 33514628

Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmalı A, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, et al. 2021. Dexamethasone in Hospitalized Patients with Covid-19. The New England Journal of Medicine 384:693–704. DOI: https://doi.org/10.1056/NEJMoa2021436, PMID: 32678530

REMAPP Investigators, Gordon AC, Mouncey PR, AI-Beidh F, Rowan KM, Nichol AD, Arabi YM, Anand N, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunhorsin AM, Bugazau A, Cheng AC, Detry MA, Duffy EJ, Escourt LJ, et al. 2021. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England Journal of Medicine 384:1491–1502. DOI: https://doi.org/10.1056/NEJMoa2100433, PMID: 33631065

Rivelli ED, Kivir T, Twagiramugabe T, Mueller A, Banner-Goospeed VM, Officer L, Novack V, Mutumwinka M, Talmor DS, Fowler RA. 2016. Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. American Journal of Respiratory and Critical Care Medicine 193:52–59. DOI: https://doi.org/10.1164/rccm.201503-0584OC, PMID: 26352116
Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB. 2011. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients. Journal of Immunology 187:1298–1303. DOI: https://doi.org/10.4049/jimmunol.1100857, PMID: 21705624

Schneider DS, Ayres JS. 2008. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nature Reviews. Immunology 8:889–895. DOI: https://doi.org/10.1038/nri2432, PMID: 18927577

Schulte-Schrepping J, Reusch N, Paclick D, Baßler K, Schlickeiser S, Zhang B, Krämer B, Krammer T, Brumhard S, Bonaguro L, De Domenico E, Wendisch D, Grasshoff M, Kapellos TS, Beckstette M, Pech T, Saglam A, Dietrich O, Mei HE, Schulz AR, et al. 2020. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell 182:1419-1440. DOI: https://doi.org/10.1016/j.cell.2020.08.001, PMID: 32810438

Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805–820. DOI: https://doi.org/10.1016/j.cell.2010.01.022, PMID: 20303872

Therneau TM. 2020. A Package for Survival Analysis in R. Survival. https://cran.r-project.org

Vallania F, Tam A, Lofgren S, Schaffert S, Azad TD, Bengen E, Haynes W, Alsup M, Alonso M, Davis M, Engleman E, Khatri P. 2018. Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. Nature Communications 9:4735. DOI: https://doi.org/10.1038/s41467-018-07242-6, PMID: 30413720

Villar J, Ferrando C, Martínez D, Ambrosó A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higuera E, Conesa LA, Martín-Rodríguez C, Díaz-Dominguez FJ, Serna-Grande P, Rivas F, Ferreres J, Beleda J, Capilla L, Tallet A, Añón JM, Fernández RL, et al. 2020. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. The Lancet. Respiratory Medicine 8:267–276. DOI: https://doi.org/10.1016/S2213-2600(19)30417-5, PMID: 32043986

Wawrusiewicz-Kuryłonek N, Goićik J, Chorąży M, Siewko K, Posmyk R, Zajkowska A, Citko A, Macielewski R, Szczepańska M, Myśliwiec J, Jastrzębska I, Kulakowska A, Kočanowicz J, Krótski AJ. 2020. The interferon-induced helicase C domain-containing protein 1 gene variant (rs1990760) as an autoimmune-based pathology susceptibility factor. Immunobiology 225:151864. DOI: https://doi.org/10.1016/j.imbio.2019.10.013, PMID: 31733941

Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, Dong L, Cui X, Miao Y, Wang D, Dong J, Xiao C, Chen W, Wang H. 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discovery 6:31. DOI: https://doi.org/10.1038/s41421-020-0168-9, PMID: 32377375

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Steyne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azavedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Embersen J, Fisher D, Giraudreau B, Gordon AC, Granholm A, Green C, Haynes R, et al. 2020. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 324:1330–1341. DOI: https://doi.org/10.1001/jama.2020.17023, PMID: 32876694

Wickham H. 2016. Ggplot2: Elegant Graphics for Data Analysis. Cham: Springer-Verlag. DOI: https://doi.org/10.1007/978-3-319-24277-4

Wilk AJ, Rustagi A, Zhao NQ, Roque J, Martínez-Colón GJ, McKechnie JL, Ivison GT, Ranganath T, Vergara R, Hollis T, Simpson LJ, Grant P, Rogers AJ, Blish CA. 2020. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature Medicine 26:1070–1076. DOI: https://doi.org/10.1038/s41591-020-0944-y, PMID: 32514174

Wu B, Peisley A, Richards C, Yao H, Zeng X, Lin C, Chu F, Walz T, Hur S. 2013. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 152:276–289. DOI: https://doi.org/10.1016/j.cell.2012.11.048, PMID: 23273991

Xiao K, Zhai J, Peng Y, Zhou N, Zhang X, Zou J-J, Li N, Guo Y, Li X, Shen X, Zhang Z, Shu F, Huang W, Li Y, Zhang Z, Chen R-A, Wu Y-J, Peng S-M, Huang M, Xie W-J, et al. 2020. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature 583:286–289. DOI: https://doi.org/10.1038/s41586-020-2313-x, PMID: 32380510

Yin X, Riva L, Pu Y, Martin-Sancoho L, Kanamune Y, Yamamoto Y, Sakai K, Gotoh S, Miorini D, De Jesus PD, Yang CC, Herbert KM, Yoh S, Hultquist JF, Garcia-Sastre A, Chanda SK. 2021. MDAS Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Reports 34:108628. DOI: https://doi.org/10.1016/j.celrep.2020.108628, PMID: 33440148

Zhang J, Liu X, Meng Y, Wu H, Wu Y, Yang B, Wang L. 2018. Autoimmune disease associated IFIH1 single nucleotide polymorphism related with IL-18 serum levels in Chinese systemic lupus erythematosus patients. Scientific Reports 8:9442. DOI: https://doi.org/10.1038/s41598-018-27782-7, PMID: 29930927

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabili IKD, Hodeib S, Koroši C, Rosain J, Bilguvar K, Ye J, Bolze A, Bigio B, Yang R, Arias AA, Zhou Q, Zhang Y, Onodl F, et al. 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570. DOI: https://doi.org/10.1126/science.abd4570
Appendix 1

Hazard ratio estimation and in-silico clinical trials

Estimation of hazard ratios from the RECOVERY trial

Our findings raise the hypothesis that steroid therapy will have a larger effect in populations with a low proportion of individuals with a TT genotype. Populations with black/Asian ancestry have an allelic frequency of the T allele of 0.13 (COVID-19 GWAS Results. https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx). Therefore, the frequency of a TT genotype is 0.017, implying that the majority of the population has a CC/CT variant. Using data from the RECOVERY trial, we assume that the effects of steroids in this population correspond to the effect on patients with a CC/CT variant. In this population, steroids significantly decreased mortality, with a RR of 0.7 (0.51–0.95). Therefore, we assumed that treatment with steroids in patients with these non-TT variants decreases mortality with a RR of 0.7.

White populations have an allelic frequency of the T allele in rs1990760 of 0.61 (COVID-19 GWAS Results. https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx). Therefore, the proportion of patients with a TT variant is 0.37. GWAS data released by the UK biobank report a coefficient for hospital death in patients with a T allele (compared to positive survivors) of 0.03 (COVID-19 GWAS Results. https://grasp.nhlbi.nih.gov/downloads/COVID19GWAS/05092021/top_UKBB_death_ALLpvalue_050921.txt.gz), so the RR for a TT variant (irrespective of the therapy) is $e^{2 \times 0.03} = 1.06$. Translating these findings to white patients included in the RECOVERY trial yields the following mortality table (assuming that randomization was independent of the rs1990760 variant):

| Genotype | Patients | Standard care | Dexamethasone |
|----------|----------|---------------|---------------|
| CC/CT    | 2954     | 573/1978      | 203/574       |
| TT       | 1735     | 276/1161      | 198/976       |

From these values, the RR of a TT genotype compared to CC/CT variants in patients not receiving steroids is:

$$RR_{(TT \to CC\text{, No steroids})} = \frac{276}{203} \div \frac{1161}{1161} = 0.821$$

And the RR related to steroid therapy compared to standard care in patients with a TT variant is:

$$RR_{(Dexamethasone vs std. care \text{, TT variant})} = \frac{203}{276} \div \frac{976}{976} = 1.487$$
In-silico clinical trials
The previously estimated RRs were used to simulate mortality curves and perform in-silico clinical trials. Mortality was modeled using an asymptotic regression curve with a cumulative distribution function:

\[ F(x) = a - ae^{-ct} \]

where \( a \) is the upper asymptote, \( c \) is a curvature parameter, \( e \) is the base of natural logarithms and \( t \) is time. Assuming that final mortality (this is, the upper asymptote) is 10% higher than the observed mortality at day 28 (as in the survival curves of our cohort), we obtain that the curvature parameter is 0.08564. This parameter is constant for all curves, so the differences among groups depend only on the upper asymptote. This model is appropriate to fit acute conditions in which most of the deaths occur in the short term, but a substantial proportion of patients survive the disease. The code for these simulations can be found at https://github.com/Crit-Lab/IFIH1_simulation (copy archived at swh:1:rev:343c92a4ce58b831df7b289bf40b539db5298d0a, Crit-Lab, 2022).

Different clinical trials including patients randomized into four groups depending on the rs1990760 variant (CC/CT or TT) and prescription of dexamethasone were simulated. Randomization to dexamethasone or placebo was 1:1. Minor allele frequencies from 0.13 to 0.61 (corresponding to populational distributions) and two baseline mortality rates (by adjusting the mortality of patients with a CC/CT variant not treated with steroids to 25.7% and 41.4%, corresponding to mortality rates of the overall RECOVERY trial and those receiving mechanical ventilation respectively) were tested. Each set of conditions was repeated 1000 times and the average RR was calculated. All the simulations were done using the Mediana package for R (available at https://CRAN.R-project.org/package=Mediana).